Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

Wedbush analyst Robert Driscoll has downgraded Compass Therapeutics (NASDAQ: CMPX) from Outperform to Neutral. The price target for the stock has been reduced significantly from $5 to $1.